Test the Drug.
Match the Patient.
We enable a future where therapies are validated in human-relevant models before reaching clinical trials — accelerating discovery while protecting patients.
The 3R for Humans
Reduce
Patient exposure to ineffective treatments.
Refine
Clinical trial design through better patient selection.
Replace
Non-predictive models with human-relevant systems.
- Almi-supported startup
- 10+ years translational research
- Based in Sweden
Beyond Animal Models. Beyond Cell Lines.
Traditional preclinical models often fall short in predicting human drug response — contributing to high attrition rates across clinical development. Patient-derived organoids offer a fundamentally more translatable alternative. By recapitulating the patient's own tumor biology in vitro, we enable earlier evaluation of drug efficacy and generate actionable insights that strengthen decision-making well before the first-in-human dose.
Human Relevance
Patient-derived organoids retain key genetic and functional characteristics of human tumors — generating preclinical data with substantially improved translational relevance.
Faster Go/No-Go Decisions
Enable earlier, evidence-based pipeline decisions — before costly in vivo studies or clinical trials — reducing both development risk and expenditure.
Regulatory-Aligned Approach
The FDA and EMA increasingly support New Approach Methodologies (NAMs) as alternatives to conventional animal models. Our human-biology-first platform positions your program ahead of evolving regulatory expectations.
Sustainable Science
Complementary to conventional research, our organoid-based approach reduces reliance on animal experiments — supporting more ethical, reproducible, and sustainable drug development pipelines.
Four Ways We Accelerate Your Pipeline
Whether you're screening a compound library, profiling combinations, or planning a smarter clinical trial — we build the experiment around your scientific question, not the other way around.
Need a custom workflow? Talk to us about customised solutions →
Built for Every Stage of Drug Development
1Pharmaceutical Companies
De-risk clinical investment with organoid-based preclinical data that improves patient selection and efficacy signals before your IND.
2Biotechs & CROs
Strengthen your translational pipeline with organoid-based models to support smarter and more predictive development strategies.
3Academic Research Groups
Access advanced organoid platforms for mechanistic studies, biomarker discovery, and publications with clinical validity.
4Clinics & Oncologists
Support precision treatment decisions and clinical trial design through organoid response profiling.
4.1For Patients & Caregivers
3DxCell's organoid-based testing is available to individual patients through our clinical partners. Speak with your treating oncologist or clinical team — they can initiate a request on your behalf.
Ready to Test Your Compound on Human Tumor Models?
Tell us about your project — we'll come back with a tailored proposal.